<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3746">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04535167</url>
  </required_header>
  <id_info>
    <org_study_id>C4611001</org_study_id>
    <secondary_id>2020-003905-73</secondary_id>
    <nct_id>NCT04535167</nct_id>
  </id_info>
  <brief_title>First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.</brief_title>
  <official_title>A PHASE 1B, 2-PART, DOUBLE-BLIND, PLACEBO-CONTROLLED, SPONSOR-OPEN STUDY, TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING (24-HOUR, PART 1) AND EXTENDED (120-HOUR, PART 2) INTRAVENOUS INFUSIONS OF PF-07304814 IN HOSPITALIZED PARTICIPANTS WITH COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is Phase 1b, 2-part, double-blind, placebo-controlled study to evaluate safety,&#xD;
      tolerability, and pharmacokinetics of PF-07304814, in patients hospitalized with SARS-CoV-2&#xD;
      virus infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a 2-part study in hospitalized COVID-19 patients.&#xD;
&#xD;
        -  Part 1 is to evaluate safety, tolerability, PK and markers of clinical activity of&#xD;
           escalating doses of PF-07304814 given as 24-hour IV infusion.&#xD;
&#xD;
           2 planned and 3 optional cohorts with 8 participants each are planned.&#xD;
&#xD;
        -  Part 2 is to evaluate safety, tolerability, PK and markers of clinical activity of&#xD;
           escalating doses of PF- 07304814 given as 120-hour infusion.&#xD;
&#xD;
           2 planned and 2 optional cohorts with 8 participants each are planned&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">July 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 5, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part 1 will have 2 planned cohorts. Each escalating cohort will be initiated for enrollment after assessment of safety, tolerability and PK data from previous cohorts by an independent IRC and is deemed acceptable.&#xD;
Part 2 will have 2 planned cohort and each escalating cohort will be initiated after all safety, tolerability and PK data from previous cohort is evaluated and is deemed acceptable by a competent regulatory authority.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Adverse Events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who withdraw due to treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs), causally related to study intervention</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent serious adverse events</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Serious Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent infusion site reactions</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of abnormal hematologic laboratory findings</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Percent change in laboratory parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of abnormal chemistry values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of abnormal hematologic laboratory findings</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnitude of abnormal urinalysis findings</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Percent change in urinalysis parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in PR values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in RR values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in QTc values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in QTcF values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in QRS values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>ECG parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in pulse rate measurements</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Vital sign measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in temperature values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Vital sign measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in respiratory rate values</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Vital sign measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in systolic blood pressure</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Vital sign measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in diastolic blood pressure</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Vital sign measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in pulse oximetry/SpO2 measurement</measure>
    <time_frame>0 hours up to 41 days</time_frame>
    <description>Vital sign measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in concentration at 24 hours (C24 [end of infusion]) of PF-07304814 and PF-00835231</measure>
    <time_frame>0 to 28 hours</time_frame>
    <description>plasma PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration, dose normalised, at 24 hours (C24 (dn) [end of infusion]) of PF-07304814 and PF-00835231</measure>
    <time_frame>0 to 28 hours</time_frame>
    <description>plasma PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration at 120 hours (C120[end of infusion]) of PF-07304814 and PF-00835231</measure>
    <time_frame>0 to 126 hours</time_frame>
    <description>plasma PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maximum observed concentration (Cmax) of PF-07304814 and PF-00835231</measure>
    <time_frame>0 to 126 hours</time_frame>
    <description>plasma PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in concentration at steady state (Css) of PF-07304814 and PF-00835231</measure>
    <time_frame>0 to 126 hours</time_frame>
    <description>plasma PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative amount of unchanged drug excreted into urine (Ae)</measure>
    <time_frame>0 to 36 hours</time_frame>
    <description>urinary PK parameters (Cohort 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of dose excreted as unchanged drug (Ae%) over dosing period</measure>
    <time_frame>0 to 36 hours</time_frame>
    <description>urinary PK parameters (Cohort 2 only)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in terminal half life (t1/2) of PF-07304814 and PF-00835231</measure>
    <time_frame>0 to 126 hours</time_frame>
    <description>plasma PK parameters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Viral Disease</condition>
  <arm_group>
    <arm_group_label>PF-07304814</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1:&#xD;
Cohort 1-5&#xD;
Part 2:&#xD;
Cohort 6-9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1:&#xD;
Cohort 1-5&#xD;
Part 2:&#xD;
Cohort 6-9</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-07304814</intervention_name>
    <description>PF-07304814 is an anti-viral, formulated for intravenous delivery</description>
    <arm_group_label>PF-07304814</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be formulated for intravenous delivery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               1. Male or female participants between the ages of 18 and 79 years.&#xD;
&#xD;
               2. Confirmed SARS-CoV-2 infection.&#xD;
&#xD;
               3. Hospitalized for COVID-19.&#xD;
&#xD;
               4. Symptoms consistent with COVID-19 indicated by at least 1 of the following:&#xD;
                  fever, cough, sore throat, malaise, headache, muscle pain, shortness of breath,&#xD;
                  new loss of taste and smell, nausea, chills, fatigue, rhinorrhea, diarrhea,&#xD;
                  vomiting or radiographic infiltrates by imaging consistent with COVID-19&#xD;
&#xD;
               5. Total body weight &gt;=50 kg (110 lb), BMI &lt;40 kg/m2; BMI &lt;35 kg/m2 for 76- 79&#xD;
                  years.&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               1. Evidence of critical illness, defined by at least one of the following:&#xD;
                  Respiratory failure, Multi-organ dysfunction/failure, Cardiac failure or septic&#xD;
                  shock&#xD;
&#xD;
               2. Participants that are anticipated by the study Investigator to progress to&#xD;
                  critical disease, including mechanical ventilation, within 24 hours of enrolment&#xD;
&#xD;
               3. Participants with pre-existing moderate to severe cardiovascular disease,&#xD;
                  uncontrolled diabetes, or severe asthma or severe COPD.&#xD;
&#xD;
             3.Participants with a known medical history of recent acute or chronic liver disease&#xD;
             (other than NASH), chronic or active hepatitis B or C infection, or primary biliary&#xD;
             cirrhosis.&#xD;
&#xD;
             4.Participants with a known medical history of ischemic heart disease, heart failure,&#xD;
             dysrhythmia or other pre-existing cardiac condition.&#xD;
&#xD;
             5. Participants with known HIV infection, acute or chronic history of hepatitis B or&#xD;
             C.&#xD;
&#xD;
             6.Participants with a known medical history of recurrent seizures. 7. Participants&#xD;
             with history of venous thromboembolic event, including deep venous thrombosis or&#xD;
             pulmonary embolism 8.Confirmed concurrent active systemic infection other than&#xD;
             COVID-19. 9.Current diagnosis of cancer, unless in remission and untreated. 10.Other&#xD;
             medical or psychiatric condition including recent or active suicidal ideation/behavior&#xD;
             or laboratory abnormality that may increase the risk of study participation 11.Females&#xD;
             who are pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>El Camino Health</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Texas Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multicare Health System-Tacoma General Hospital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4611001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-COV-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

